secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001213900-25-075190
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.01, 3.02, 9.01, 4.01, 3.03, 5.03, 8.01, 5.01, 5.02, 5.05, 5.06, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Oncology closes SPAC merger; raises $260.9M PIPE, $381.8M total gross proceeds
--------------------------------------------------------------------------------

- Closing on Aug 11, 2025: Helix domesticated to Delaware, merged with BBOT subsidiary; new name BridgeBio Oncology Therapeutics, ticker BBOT.
- PIPE of $260.9M (24.3M shares at $10.7173) plus $120.9M trust; $76.3M redeemed by 7.1M public shares.
- Pro forma shares: ~79.2M outstanding (excluding options); ~61.1M shares (77.2%) subject to registration rights.
- Lock-up: Helix insiders 1 year; BBOT employees below VP 6 months; other BBOT holders 1 year.
- Equity plans approved: 2025 Incentive Plan (5.37M shares + evergreen) and ESPP (0.9M shares + evergreen).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/0001213900-25-075190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/ea0250662-8k_bridge.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-075190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer